Pyelonephritis - Pipeline Review, H1 2018

  • ID: 4479923
  • Report
  • 94 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Achaogen Inc
  • AstraZeneca Plc
  • Entasis Therapeutics Inc
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Merck & Co Inc
  • MORE
Pyelonephritis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Pyelonephritis - Pipeline Review, H1 2018, provides an overview of the Pyelonephritis (Infectious Disease) pipeline landscape.

Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in urethra or bladder and travels up into kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion and back pain or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract and damage to nerves around the bladder. Treatment includes antibiotics.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Pyelonephritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pyelonephritis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pyelonephritis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 4, 1 and 1 respectively.

Pyelonephritis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pyelonephritis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pyelonephritis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pyelonephritis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pyelonephritis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pyelonephritis (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pyelonephritis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pyelonephritis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Achaogen Inc
  • AstraZeneca Plc
  • Entasis Therapeutics Inc
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Merck & Co Inc
  • MORE
Introduction

Report Coverage

Pyelonephritis - Overview

Pyelonephritis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pyelonephritis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pyelonephritis - Companies Involved in Therapeutics Development

Achaogen Inc

AstraZeneca Plc

Entasis Therapeutics Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Paratek Pharmaceuticals Inc

Zavante Therapeutics Inc

Pyelonephritis - Drug Profiles

(AAI-101 + cefepime) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(avibactam + ceftazidime) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ceftolozane sulfate + tazobactam sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(meropenem + vaborbactam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETX-2514 + sulbactam sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finafloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosfomycin tromethamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nacubactam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omadacycline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plazomicin sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sulopenem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pyelonephritis - Dormant Projects

Pyelonephritis - Discontinued Products

Pyelonephritis - Product Development Milestones

Featured News & Press Releases

Feb 27, 2018 : Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE (meropenem and vaborbactam) in Patients with cUTI

Jan 30, 2018 : Achaogen Announces Upgraded Status for Plazomicin Fill Manufacturer

Oct 26, 2017: Achaogen Submits Plazomicin New Drug Application (NDA) to the U.S. FDA for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections

Oct 05, 2017: The Medicines Company to Present New Data from TANGO II Study of VABOMERE™ (meropenem and vaborbactam) at IDWeek 2

Oct 05, 2017: Achaogen IDWeek 2017 Presentations Feature Plazomicin’s Unique Potential to Treat MDR Enterobacteriaceae

Oct 04, 2017: Merck Highlights Data on ZERBAXA at ID Week 2

Sep 27, 2017: Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2

Aug 30, 2017: The Medicines Company Announces FDA Approval of VABOMERE (meropenem and vaborbactam)

Jun 05, 2017: Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting

Apr 17, 2017: The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam

Jan 30, 2017: FDA Approves Allergan's sNDA for AVYCAZ (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections, Including Pyelonephritis

Oct 26, 2016: Merck Highlights Data Presentation on ZERBAXA at ID Week 2

Oct 11, 2016: FDA Accepts Supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam)

Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections

Jun 15, 2016: Merck Presents Data on ZERBAXA (ceftolozane and tazobactam) at ASM Microbe 2

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Pyelonephritis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pyelonephritis - Pipeline by Achaogen Inc, H1 2018

Pyelonephritis - Pipeline by AstraZeneca Plc, H1 2018

Pyelonephritis - Pipeline by Entasis Therapeutics Inc, H1 2018

Pyelonephritis - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018

Pyelonephritis - Pipeline by Melinta Therapeutics Inc, H1 2018

Pyelonephritis - Pipeline by Merck & Co Inc, H1 2018

Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2018

Pyelonephritis - Pipeline by Paratek Pharmaceuticals Inc, H1 2018

Pyelonephritis - Pipeline by Zavante Therapeutics Inc, H1 2018

Pyelonephritis - Dormant Projects, H1 2018

Pyelonephritis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Pyelonephritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Achaogen Inc
  • AstraZeneca Plc
  • Entasis Therapeutics Inc
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Merck & Co Inc
  • MerLion Pharmaceuticals Pte Ltd
  • Paratek Pharmaceuticals Inc
  • Zavante Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll